In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.76 below Allogene Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Quick Ratio than Allogene Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 93, from total ranking in the second quarter 2026 at 353.

Explain Quick Ratio?
How much Cash & cash equivalents ALLO�s has?
What are ALLO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ALLO/financial-strength

https://api.csimarket.com/api/v1/companies/ALLO/fundamentals

https://api.csimarket.com/api/v1/companies/ALLO/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ALLO Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	20.94 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-88.39 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.76	Subscribe	Subscribe	Subscribe	Subscribe
ALLO's Total Ranking	# 93	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	21.34 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-97.43 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 3
Healthcare Sector	# 17
Overall Market	# 93

Quick Ratio Statistics
High	Average	Low
35.83	12.32	1.53
(Jun 30 2026)		(Sep 30 2018)

Financial Statements
Allogene Therapeutics Inc 's Current Liabilities	$ 38 Millions	Visit ALLO's Balance sheet
Allogene Therapeutics Inc 's Cash & cash equivalent	$ 29 Millions	Visit ALLO's Balance sheet
Source of ALLO's Sales		Visit ALLO's Sales by Geography

Cumulative Allogene Therapeutics Inc 's Quick Ratio

ALLO's Quick Ratio for the trailling 12 Months

ALLO Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	1.56 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	53.31 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	12.84	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3130	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	5.36 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-11.7 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ALLO Financial Strength Comparisons >> Go to Compare ALLO Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $38.50 millions, cumulative Quick Ratio decreased to 12.84 above the ALLO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 132 other companies have achieved higher Quick Ratio than Allogene Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3130, from total ranking during the twelve months ending second quarter 2026 at 3460.

Explain Quick Ratio?
How much Cash & cash equivalents ALLO�s has?
What are ALLO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 133
Healthcare Sector	# 822
Within the Market	# 3130

trailing twelve months Quick Ratio Statistics
High	Average	Low
18.31	11.33	4.32
(Sep 30 2020)		(Mar 31 2019)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Biocryst Pharmaceuticals Inc	1.92	$ 375.334 Millions	$ 195.830 Millions
Novavax inc	1.89	$ 622.363 Millions	$ 329.845 Millions
Lenz Therapeutics Inc	1.78	$ 31.610 Millions	$ 17.750 Millions
Acumen Pharmaceuticals Inc	1.74	$ 78.604 Millions	$ 45.087 Millions
Sana Biotechnology Inc	1.63	$ 121.728 Millions	$ 74.880 Millions
Aligos Therapeutics Inc	1.59	$ 31.094 Millions	$ 19.600 Millions
Tarsus Pharmaceuticals Inc	1.36	$ 309.612 Millions	$ 227.114 Millions
Amgen Inc	1.11	$ 25,811.000 Millions	$ 23,231.000 Millions
Coherus Oncology inc	1.11	$ 83.629 Millions	$ 75.636 Millions
Sab Biotherapeutics Inc	0.98	$ 14.438 Millions	$ 14.798 Millions
Bio techne Corp	0.97	$ 350.036 Millions	$ 361.269 Millions
C4 Therapeutics Inc	0.81	$ 33.492 Millions	$ 41.460 Millions
Allogene Therapeutics Inc	0.76	$ 29.270 Millions	$ 38.498 Millions
Ocugen Inc	0.71	$ 84.257 Millions	$ 118.901 Millions
Neurocrine Biosciences Inc	0.59	$ 739.100 Millions	$ 1,242.800 Millions
Iovance Biotherapeutics inc	0.55	$ 57.934 Millions	$ 105.774 Millions
Agenus Inc	0.43	$ 86.936 Millions	$ 203.691 Millions
Vaxcyte Inc	0.42	$ 125.470 Millions	$ 295.697 Millions
Vaxart Inc	0.41	$ 30.435 Millions	$ 73.934 Millions
Surrozen Inc	0.35	$ 100.353 Millions	$ 286.684 Millions
Biogen Inc	0.16	$ 628.100 Millions	$ 3,898.400 Millions

Date modified: 2026-11-07T06:16:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.